Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from the DISCOVER and PSUMMIT Trials

Pushpike Thilakarathne,Agata Schubert,Steve Peterson,Wim Noel,Barkha P. Patel,Fareen Hassan

DOI: https://doi.org/10.1007/s40744-024-00644-7

2024-02-28

Rheumatology and Therapy

Abstract:IntroductionTwo biologic therapies for psoriatic arthritis (PsA), guselkumab and ustekinumab, have demonstrated superior efficacy versus placebo in clinical trials. However, no head-to-head studies have been conducted comparing these two treatments for PsA. The objective was to indirectly compare guselkumab and ustekinumab on joint and skin efficacy up to week 52, using pooled individual patient-level data (IPD) from PsA trials.MethodsIPD, including baseline characteristics, American College of Rheumatology (ACR) scores and Psoriasis Area Severity Index (PASI) response from guselkumab (DISCOVER-1 and -2) and ustekinumab (PSUMMIT 1 and 2) trials were pooled. Differences in patient characteristics across trials were adjusted using multivariate logistic regression. Odds ratios (OR) were used to derive absolute response probabilities in the guselkumab trial population and were presented with 95% confidence intervals.ResultsMost baseline characteristics for guselkumab-treated patients (100 mg every 8 weeks [Q8W]; 100 mg every 4 weeks [Q4W]) were comparable to ustekinumab-treated patients (45/90 mg). In biologic-naïve patients, both guselkumab doses showed significantly higher ACR 20 (Q8W: 1.97; 1.37, 2.84; Q4W: 2.04; 1.40, 2.96) and PASI 90 (Q8W: 2.33; 1.52, 3.56; Q4W: 2.57; 1.67, 3.97) versus ustekinumab from week 16 onwards. In biologic-experienced patients, both guselkumab doses showed significantly higher ACR 20 (Q8W: 2.57; 1.11, 5.93; Q4W: 2.63; 1.12, 6.17) versus ustekinumab from week 24 onwards; for PASI 90, both guselkumab doses were superior to ustekinumab at week 16 and 52 (Q8W: 3.96; 1.39, 11.27; Q4W: 13.10; 4.18, 41.04). Guselkumab efficacy was similar and robust across primary, scenario, and sensitivity analyses.ConclusionsIPD analysis demonstrated that both guselkumab doses were superior to ustekinumab for ACR 20 from weeks 16 (biologic-naïve) and 24 (biologic-experienced) onwards, and for PASI 90 at weeks 16 and 52 for both subgroups.

rheumatology

What problem does this paper attempt to address?

This paper aims to compare the efficacy of two biologic therapies, guselkumab and ustekinumab, for the treatment of psoriatic arthritis (PsA). Currently, there is no direct head-to-head study comparing these two treatment approaches. The study analyzed the impact of both drugs on joint and skin efficacy within 52 weeks by merging individual patient data (IPD) from the DISCOVER and PSUMMIT trials.

In biologic-naïve patients, both doses of guselkumab (100 mg every 8 weeks and 100 mg every 4 weeks) demonstrated significantly higher American College of Rheumatology 20 response rate (ACR20) and Psoriasis Area and Severity Index 90 response rate (PASI90) compared to ustekinumab after week 16. In biologic-experienced patients, starting from week 24, both doses of guselkumab also showed higher ACR20 response rates compared to ustekinumab, while the PASI90 response rate demonstrated superiority at both week 16 and week 52.

Sensitivity analysis further confirmed these results, indicating that guselkumab generally outperformed ustekinumab in terms of joint and skin effects, regardless of the primary analysis or different hypothetical scenarios.

In conclusion, this IPD analysis suggests that guselkumab may be more effective than ustekinumab in improving joint and skin symptoms in patients with psoriatic arthritis over the long-term treatment.